Verition Fund Management LLC Cuts Stock Position in GH Research PLC (NASDAQ:GHRS)

Verition Fund Management LLC decreased its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 7.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 1,057,782 shares of the company’s stock after selling 82,850 shares during the period. Verition Fund Management LLC’s holdings in GH Research were worth $7,077,000 at the end of the most recent reporting period.

Separately, Lynx1 Capital Management LP raised its position in GH Research by 19.8% during the second quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company’s stock worth $46,252,000 after acquiring an additional 656,163 shares during the period. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Trading Down 3.8 %

NASDAQ:GHRS opened at $8.93 on Monday. The company has a market cap of $464.61 million, a P/E ratio of -11.30 and a beta of 0.74. GH Research PLC has a twelve month low of $5.05 and a twelve month high of $14.99. The company’s 50-day moving average price is $8.04 and its 200-day moving average price is $10.18.

GH Research (NASDAQ:GHRS) last released its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. On average, analysts expect that GH Research PLC will post -0.79 earnings per share for the current year.

Analysts Set New Price Targets

GHRS has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research report on Wednesday, November 20th. JMP Securities reiterated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. Finally, Canaccord Genuity Group decreased their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).